Allogene Initiates ALLO-501A’s Pivotal Ph2 Trial
On Thursday, October 6, Allogene announced (press release) the initiation of ALLO-501A’s (allogeneic CD19 CAR-T) potentially pivotal Ph2 ALPHA2 trial in patients with r/r LBCL. Additionally, management confirmed that they are in the process of initiating ALLO-647’s (anti-CD52 monoclonal antibody) EXPAND study. Below, Celltelligence provides insights on both trials, while discussing potential approval timelines for ALLO-501A.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.